ReviewHuman vaccines & immunotherapeutics2026
Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are cutting‑edge therapies in cancer treatment; however, they may trigger unique immune‑related adverse events (irAEs). Although irAEs can affect various organs, ICI‑induced cystitis/ureteritis has rarely been reported. We present a 44‑year‑old female patient with high‑grade endometrial stromal sarcoma who developed severe urinary frequency, urgency, and dysuria after three cycles of sintilimab combined with nab‑paclitaxel and carboplatin. Empirical antibiotic therapy failed to relieve her symptoms. Imaging revealed diffuse thickening of the bladder and ureteral walls with marked peri‑vesical and peri‑ureteral exudation. After treatment with methylprednisolone, the patient's symptoms improved dramatically. A subsequent urine culture grew Enterococcus faecalis, and the addition of piperacillin-tazobactam resulted in further symptom resolution. Following symptom resolution, she was rechallenged with sintilimab and developed only mild urinary tract symptoms. Subsequently, due to disease progression, treatment was switched to tislelizumab, and the urinary symptoms did not recur. The patient's urinary symptoms were sintilimab‑related cystitis/ureteritis with possible concomitant or partially suppressed bacterial infection. This case, together with a structured literature review of other immunotherapy‑related cystitis/ureteritis cases and subsequent ICI use, provides a practical reference for the diagnosis and management of ICI‑related urological irAEs and for subsequent anti‑tumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.